Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Ovarian Epithelial × adavosertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 3 Small Cell Lung Carcinoma 2 Neoplasms 2 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Advanced Malignant Solid Neoplasm 2 Uterine Neoplasms 1 Triple-negative Metastatic Breast Cancer 1 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1 Neoplasm Metastasis 1 Myelodysplastic-Myeloproliferative Diseases 1 Multiple Myeloma 1 Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Chromosome 5q Deletion Syndrome 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Brenner Tumor 1

Interventions

Carboplatin 41 Paclitaxel 39 Cisplatin 20 Topotecan 15 Gemcitabine 14 Docetaxel 11 Bevacizumab 11 olaparib 6 pembrolizumab 5 liposomal doxorubicin 5 Surgical Procedures, Operative 5 Etoposide 5 Drug Therapy 5 Cyclophosphamide 5 Amifostine 5 catumaxomab 4 Hyperthermic Intraperitoneal Chemotherapy 4 sargramostim 3 rucaparib 3 oregovomab 3 ixabepilone 3 Standard of Care 3 Methylprednisolone 3 Immunohistochemistry 3 Imatinib Mesylate 3 Filgrastim 3 Erlotinib Hydrochloride 3 Cytoreduction Surgical Procedures 3 Capecitabine 3 Albumin-Bound Paclitaxel 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01164995 2023-09-07

M10MKO

The Netherlands Cancer Institute

Phase 2 Completed

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡